Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects
2012 (English)In: Neuropharmacology, ISSN 0028-3908, E-ISSN 1873-7064, Vol. 62, no 1, 347-357 p.Article in journal (Refereed) Published
Excessive activation of the hypothalamic pituitary adrenal (HPA) axis has been associated with numerous diseases, including depression, and the tricyclic antidepressant imipramine has been shown to suppress activity of the HPA axis. Central hypothalamic control of the HPA axis is complex and involves a number of neuropeptides released from multiple hypothalamic subnuclei. The present study was therefore designed to determine the effects of imipramine administration on the mouse hypothalamus using a peptidomics approach. Among the factors found to be downregulated after acute (one day) or chronic (21 days) imipramine administration were peptides derived from secretogranin 1 (chromogranin B) as well as peptides derived from cerebellin precursors. In contrast, peptides SRIF-14 and SRIF-28 (1-11) derived from somatostatin (SRIF, somatotropin release inhibiting factor) were significantly upregulated by imipramine in the hypothalamus. Because diminished SRIF levels have long been known to occur in depression, a second part of the study investigated the roles of individual SRIF receptors in mediating potential antidepressant effects. SRA880, an antagonist of the somatostatin-1 autoreceptor (sst1) which positively modulates release of endogenous SRIF, was found to synergize with imipramine in causing antidepressant-like effects in the tail suspension test. Furthermore, chronic co-administration of SRA880 and imipramine synergistically increased BDNF mRNA expression in the cerebral cortex. Application of SRIF or L054264, an sst2 receptor agonist, but not 1,803807, an sst4 receptor agonist, increased phosphorylation of CaMKII and GluR1 in cerebrocortical slices. Our present experiments thus provide evidence for antidepressant-induced upregulation of SRIF in the brain, and strengthen the notion that augmented SRIF expression and signaling may counter depressive-like symptoms.
Place, publisher, year, edition, pages
2012. Vol. 62, no 1, 347-357 p.
Peptidomics, Hypothalamus, Depression, Antidepressants, Somatostatin, SRIF
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-163636DOI: 10.1016/j.neuropharm.2011.08.004ISI: 000296826800039OAI: oai:DiVA.org:uu-163636DiVA: diva2:466697
This article is part of a Special Issue entitled ‘Anxiety and Depression’.2011-12-162011-12-132013-02-07Bibliographically approved